Trefoil Therapeutics, Inc.

Trefoil Therapeutics, Inc. is a biotechnology company focused on innovative therapies that aim to restore vision for patients with corneal diseases. Founded in 2014 in San Diego, US, Trefoil Therapeutics specializes in developing vision-restoring therapies. The company has raised USD 28 mn in Series A funding in December 2021 from investors including AJU IB Investment and Access Industries.

The CEO, David Eveleth, leads the company, which has completed 4 funding deals to date. Trefoil Therapeutics specializes in developing therapies to restore vision for patients with corneal diseases, focusing on TTHX1114, an engineered Fibroblast Growth Factor (FGF1). This includes development of an intracameral injection for corneal endothelial decompensation and a topical formulation for ocular surface damage. The company targets healthcare institutions and ophthalmic specialists in the U.

S. and other markets where corneal diseases are prevalent. Trefoil Therapeutics has raised a total of USD 45 mn through two rounds of financing, along with a Collaborative Research and Development Agreement (CRADA) with the NIH and a U. S.

Department of Defense grant. Revenue is expected from the sale of investigational products and potential licensing agreements once regulatory approval is obtained. The flagship product, TTHX1114, aims to be integrated into treatment regimens within ophthalmic clinics and hospitals. Following the Series A funding round in December 2021, Trefoil Therapeutics plans to utilize the USD 28 mn raised to expand its STORM clinical program and begin clinical trials for its topical formulation.

The company is focused on enhancing its product offerings and intends to explore new markets and regions for expansion, although specific target markets and dates have not been disclosed.